NEW YORK, March 3, 2014 /PRNewswire/ -- Reportlinker.com
announces that a new market research report is available in its
catalogue:
Pharmaceutical Industry in China - Cutting-Edge Analysis of
Multinational and Chinese Pharma Companies, Industry Trends,
Environment, Regulation, Market Drivers, Restraints, Opportunities
& Challenges
http://www.reportlinker.com/p01859471/Pharmaceutical-Industry-in-China---Cutting-Edge-Analysis-of-Multinational-and-Chinese-Pharma-Companies-Industry-Trends-Environment-Regulation-Market-Drivers-Restraints-Opportunities--Challenges.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
"Pharmaceutical Industry China – Cutting-Edge Analysis of
Multinational and Chinese Biopharma Companies, Industry Trends,
Environment, Regulation, Market Drivers, Restraints, Opportunities
& Challenges" provides you with a detailed investigation of the
market size, segmentation, key players, SWOT analysis, influential
Government policies, and business and economic environments. The
report is supported by over 199 tables & figures within 153
pages. The Chinese biopharmaceutical market is presented as
follows:
• By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN,
SHANGHAI HUAGUAN BIOCHIP, SIBIONO
GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)• By Therapeutic
Area (e.g., Anti-infective, Cancer, Diabetes, Dementia,
Depression)
A wealth of financial information is provided
including:
• Company financials, sales & revenue figures – historical
to Q2•2013• China GDP, economic growth, export (bulk drug,
formulations) figures• Indian health expenditure as a function of
GDP• Growth change figures of emerging and developing countries
(India, Russia, China, Brazil)• Economic growth figures of advanced
economies (USA, UK, Germany, France, Italy, Spain,
Japan, Canada)• Projected figures of strategic
emerging industry GDP percentage contribution
SWOT, Economic and Business Environment specifics
include:
• Key strengths, weaknesses and threats influencing leading
player position within the market• Top Five Contract Pharmaceutical
Export Markets of China• Major players within China's leading
therapeutic markets (e.g., cancer, allergy, liver disease)•
Multinational penetration into the Chinese Pharma Market•
Comprehensive product portfolios, R&D activity and pipeline
therapeutics • M&A activity and future strategies of top
Chinese pharmacos• Economic indicators, trade policy, merchandise
and commercial trade statistics• Gross Domestic Product of China,
historic and projection analysis• Chinese economic outlook in
comparison to advanced economies • Three Tier 'Pharmerging' Markets
with Potential for Significant Growth • Prescription drug sales
distribution channels in China• Major biogeneric products in
China
This report highlights a number of significant Chinese and
multinational pharmacos and gives details of their operations,
products, financials and business strategy.
• Amoytop Biotech• Active Pharmaceutical Products• Beijing
Continent Pharmaceuticals• FusoGen Pharmaceuticals• Shanghai
Huaguan Biochip• SiBiono GeneTech• Abbott• AstraZeneca• Boehringer
Ingelheim• Eli Lilly• GlaxoSmithKline• Johnson & Johnson
Medical• Merck• Novartis• Pfizer• Roche
Forecast projections and future growth rates are provided to
give you a forthcoming perspective of this growing industry.
Current developments relating to patent expirations, government
funding, and regulations are discussed. The emerging trends that
appear in key sub-markets such as generics, oncology,
cardiovascular, diabetes and vaccines are elucidated and
analysed.
What you will gain:
• An in-depth understanding of the Chinese biopharmaceutical market
and it's environment
• Current market facts, figures and product lines of key players
in the industry
• An insight into how generic therapeutics will propagate the
Chinese biopharmaceutical market
• Knowledge of how the Chinese pharma market will integrate into
the global healthcare market
• Information on key regulatory and government policies
• Data on levels of private and publically funded biopharma
studies in China
• Strategies on how to adapt and restructure current business
models to this industry
This report tackles key concerns to the Chinese
biopharmaceutical market such as:
• Lack of regulatory policy and legislation
• Reimbursement schemes and payers concerns
• Funding and government sponsorship issues
• International scepticism of Chinese safety and efficacy
therapeutic profiles
This report will tell you if the companies mentioned
are:
• Strong, competitive players
• Pooling their resources for specific growth and therapeutic
areas
• Investing strategically in R&D
• Have a history of strategic M&A activity
1.0 Summary 81.1 Objectives of Report 81.2 Scope of Study 91.3
Data Sources and Methodology 101.4 Key Findings and Observations
101.5 Executive Summary 112.0 Chronic Disease Prevalence Statistics
143.0 Business Environment 163.1 Economic Indicators, Trade Policy
and Merchandise and Commercial Trade Statistics 163.2 Gross
Domestic Product of China, Historic and Projection Analysis 183.3
Annual Health Expenditure in China, Historic and Projected Analysis 193.4
Global and Chinese Economic Outlook 2010-2013 203.5 Chinese
Economic Outlook in Comparison to Emerging Markets and Developing
Countries 213.6 Chinese Economic Outlook in Comparison to Advanced
Economies (US, Europe) 234.0
Chinese Pharmaceutical Market 284.1 Market Overview 284.2 Main
Players in China's Pharmaceutical Industry 314.3 Anti-Allergy Drug
Market 314.4 Asthma Drug Market 324.5 Benign Prostate Hyperplasia
Drug Market 324.6 Anti-Depressant Drug market 334.7 Dermatitis Drug
Market 354.8 Diabetes Drug Market 364.9 Hypertension Drug Market
374.10 Dyslipidaemia Drug Market 384.11 Senile Dementia Drug Market
394.12 Cancer Drug Market 404.13 Rheumatoid Arthritis Drug Market
404.14 Ophthalmological Drug Market 414.15 Liver Disease Drug
Market 434.16 Antibiotic Drug Market 445.0 Government and
Regulation Environment 455.1 12th Five Year Plan 455.2 Intellectual
Property for Pharmaceuticals in China 475.3 State Food and Drug Administration
(SFDA) 525.4 Pharmaceutical Distribution Process in China 556.0 China – Third Largest Pharma
Market 2012 586.1 China – At the Forefront of Emerging Markets
586.2 Generic Medication Market and China 586.3 Novel Product Drug
Development 606.4 Drug Development Cost and Outsourcing 626.5 Drug
Development Case Study - Beijing Continent Pharmaceuticals 636.6
China's Pharmaceutical Export Market 636.7 Spot Light - China
Medical City Taizhou 657.0 Global Pharmaceutical Companies Interest
in China 677.1 Abbott China 677.2 AstraZeneca China 767.3 Bayer
China 847.4 Boehringer Ingelheim China 887.5 Eli Lilly China 927.6
GlaxoSmithKline China 947.7 Johnson & Johnson Medical China
997.8 Merck China 1047.9 Novartis
China 1077.10 Novo Nordisk China 1117.11 Pfizer China
1147.11.1 Pfizer China R&D Centre 1167.11.2 Pfizer China
Products 1167.11.3 Pfizer Financials 1197.11.4 Pfizer Global
1207.12 Roche China 1217.13 Sanofi China 1278.0 Chinese
Pharmaceutical Companies 1318.1 Amoytop Biotech 1318.2 Active
Pharmaceutical Products 1338.2.1 Research and Development 1348.2.2
Financial Information 1348.3 Beijing Continent Pharmaceuticals
1348.4 FusoGen Pharmaceuticals 1358.4.1 Financial Information
1368.5 Shanghai Huaguan Biochip 1368.5.1 Financial Information
1398.6 SiBiono GeneTech 1398.6.1 Financial Information 1408.7
Sinovac Biotech 1408.7.1 Financial Information 1428.7.2 New
Products 1478.7.3 Split Virion Pandemic Influenza Vaccine 1478.7.4
RabEnd 1478.7.5 Pipeline Portfolio 1478.7.6 EV71 virus Vaccine
1478.7.7 Pneumococcal Conjugate Vaccine 1488.7.8 Pneumococcal
Polysaccharide Vaccine 1488.7.9 Varicella Vaccine 1488.7.10
Measles, Mumps and Rubella Vaccines 1488.7.11 Rotavirus Vaccine
1489.0 Drivers, Restraints, Challenges and Opportunity Analysis
1499.1 Key Drivers of the Pharmaceutical Market in China 1499.2 Key Restraints of the
Pharmaceutical Market in China
1509.3 Challenges of the Pharmaceutical Industry in China 1519.4 Opportunities Within BioPharma
China 153
List of Tables
Table 2.1: Most Prominent Cancer Manifestations in China 15Table 2.2: Top Fifty Diseases in
China Today (non-cancer) 15Table
2.3: Top Infectious Disease States in China Today 15Table 3.1: World Trade
Organisation Basic Indicators on China 16Table 3.2: World Trade
Organisation Trade Policy of China 16Table 3.3: World Trade
Organisation Merchandise Trade Statistics: China 17Table 3.4: World
Trade Organisation Commercial Services Trade Statistics: China
17Table 3.5: Summary of International Monetary Fund Members' Quota,
Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending
Arrangements, Projected Payments Due and Monthly Historical
Transactions of China 18Table 3.6: China Statistics 18Table 4.1:
Top Global Pharma Markets 2003-2013 28Table 4.2: Major Players in
China's Anti-Allergy Drug Market 31Table 4.3: Major Players in
China's Asthma Drug Market 32Table 4.4: Major Players in China's
Benign Prostate Hyperplasia (BPH) Drug Market 33Table 4.5: Major
Players in China's Anti-Depressant Drug Market 34Table 4.6:
Prescription Dermatitis Drug Industry Sub-Markets and Associated
Therapeutics 35Table 4.7: Top Prescription Dermatitis Drugs on the
Chinese Market 35Table 4.8: Major Players in China's Dermatitis
Drug Market 35Table 4.9: Major Players in China's Diabetic Drug
Market 37Table 4.10: Major Players in China's Hypertension Drug
Market 38Table 4.11: Major Players in China's Dyslipidaemia Drug
Market 38Table 4.12: Major Players in China's Senile Dementia Drug
Market 39Table 4.13: Major Players in China's Cancer Drug Market
40Table 4.14: Major Players in China's Rheumatoid Arthritis Drug
Market 41Table 4.15: Major Players in China's Ophthalmological Drug
Market 42Table 4.16: Major Players in China's Liver Disease Drug
Market 43Table 4.17: Major Players in China's Antibiotic Drug
Market 44Table 5.1: Seven Strategic Emerging Industries of China's
12th Five Year Plan 2011-2015 45Table 5.2: Outline of the Chinese
Promotion Plan for the Implementation of the National Intellectual
Property Strategy, 2012 47Table 5.3: Challenges facing the
Pharmaceutical Distribution Business in China 55Table 5.4: Prescription Drug Sales
Distribution Channels in China
55Table 6.1: Major Biogeneric Products in China 59Table 6.2: Imported Therapeutics with
Administrative Protection in China
59Table 6.3: Expired Proprietary Pharmaceuticals in China 60Table 6.4: Reasons Why Multinational
Companies Seek CMO's in China
62Table 6.5: Comparison of Clinical Trial Cost between China and
the USA 63Table 6.6: Five
Functional Districts of China Medical City 65Table 6.7: Five Key
R&D and Manufacturing Areas within China Medical City 66Table
7.1: Top Multinational Company Performance, China 67Table 7.2:
Abbott Areas of Expertise 69Table
7.3: Abbott Key Global Products 72Table 7.4: AbbVie (Abbott)
Speciality Care Products Holding Market-Leading Positions 72Table
7.5: Abbott China Anaesthesia Product Profile 72Table 7.6: Abbott
China Cardiovascular Product Profile 72Table 7.7: Abbott China
Vaccine Product Profile 73Table 7.8: Abbott China Digestion Product
Profile 73Table 7.9: Abbott China HIV Product Profile 73Table 7.10:
Abbott Rheumatology HIV Product Profile 73Table 7.11 Abbott China
Gynaecological Product Profile 73Table 7.12 Abbott China Urological
Product Profile 73Table 7.13 Abbott China Liver Disease Product
Profile 73Table 7.14 Abbott China Diagnostic Product Profile
73Table 7.15: Abbott China Molecular Diagnostic Product Profile
74Table 7.16: Abbott Blood Glucose Meter Product Profile 75Table
7.17: Abbott Cardiovascular Product Profile 75Table 7.18: Abbott
Rapid Bedside Diagnostic/ Point of Care Product Profile 75Table
7.19: Important Milestones in AstraZeneca China's History 76Table
7.20: AstraZeneca China Anaesthetic Range of Products 77Table 7.21:
AstraZeneca China Cardiovascular and Metabolism Range of Products
77Table 7.22: AstraZeneca China Gastrointestinal Range of Products
77Table 7.23: AstraZeneca China Infection Range of Products 77Table
7.24: AstraZeneca China Neurology Range of Products 77Table 7.25:
AstraZeneca China Oncology Range of Products 77Table 7.26:
AstraZeneca China Respiratory Range of Products 77Table 7.27:
AstraZeneca Top Branded Pharmaceuticals Globally 80Table 7.28:
AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally
80Table 7.29: Bayer China Important Milestones 85Table 7.30:
Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in
China 86Table 7.31: Bayer -
Leading Therapeutics in China
87Table 7.32: Bayer Top Selling Consumer Health Products 88Table
7.33: Boehringer Ingelheim Major Products in China 88Table 7.34: Main Therapeutic Areas of
Interest to Boehringer Ingelheim China 89Table 7.35: Global
Therapeutic Pipeline, Boehringer Ingelheim 90Table 7.36: Major
Global Boehringer Ingelheim Therapeutic Products 91Table 7.37: Eli
Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 ($
billion) and Percentage Change 93Table 7.38: GlaxoSmithKline
Prescription Portfolio and Indications in China 94Table 7.39: GlaxoSmithKline Vaccine
Portfolio and Indications in China
95Table 7.40: GlaxoSmithKline Over the Counter Portfolio and
Indications in China 95Table 7.41:
GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area,
FY2012-2013 97Table 7.42: GlaxoSmithKline Global Vaccine Sales
FY2012-2013 98Table 7.43: Significant Milestones in Johnson and Johnson China History 100Table
7.44: Johnson & Johnson Pharmaceutical Segment Sales (US$
Billion) by Therapeutic Area and Percentage Change, 2012-2013
103Table 7.45: Merck Serono Pharmaceutical Key Therapeutic Areas in
China 104Table 7.46: Merck Serono
Fertility and Infertility Therapeutic Portfolio in China 104Table 7.47: Merck Serono Therapeutic
Portfolio in China 105Table 7.48:
Merck Pharmaceutical Hong Kong Therapeutic Portfolio 105Table 7.49:
Merck Global Pharmaceutical, Animal Health and Consumer Health
Sales 2012-2013 105Table 7.50: Merck Top Ten Global Pharmaceutical
Brand Sales 2012-2013 106Table 7.51: Range of Diabetic Products
from Novo Nordisk China 111Table 7.52: QUICKFACTs - Pfizer China
115Table 7.53: Important Milestones – Pfizer China 115Table 7.54:
Pfizer China – Range of Infectious Disease Therapeutics for Chinese
Health Care Market 116Table 7.55: Pfizer China – Range of Mental
Health Products for Chinese Health Care Market 117Table 7.56:
Pfizer China – Range of Genitourinary Products for Chinese Health
Care Market 117Table 7.57: Pfizer China – Range of Endocrine
Products for Chinese Health Care Market 117Table 7.58: Pfizer China
– Range of Women's Health Products for Chinese Health Care Market
117Table 7.59: Pfizer China – Range of Cardiovascular Disease
Products for Chinese Health Care Market 117Table 7.60: Pfizer China
– Range of Oncology Products for Chinese Health Care Market
117Table 7.61: Pfizer – Key Consumer Healthcare Global Products
118Table 7.62: Pfizer – Key Speciality Care Global Products
118Table 7.63: Pfizer – Key Oncology Global Products 118Table 7.64:
Pfizer – Key Global Established Products 118Table 7.65: Pfizer –
Key Innovative Products in Emerging Markets 118Table 7.66: Pfizer –
Key Animal Health Global Products 119Table 7.67: Pfizer Product
Sales with Significant Impact on Revenues 2012:2013 Comparison
119Table 7.68: Roche Pharmaceuticals Product List in China 122Table 7.69: Roche Global Sales (CHF
Millions) by Therapeutic Area, 2012 & 2013 and Percentage
Change (CER) 124Table 7.70: Roche Pharmaceutical Division Sales
from Brazil, China, India, Mexico, Russia, South
Korea, Turkey, 2011, 2012,
2013 and Percentage Change (CER) 126Table 7.71: Seven Growth
Platforms of Sanofi China 127Table 7.72: Key Therapeutic Areas of
Sanofi China 128Table 8.1: Important Milestones in Amoytop
Biotech's Development 131Table 8.2: Amoytop Biotech – Main
Objectives of Research and Development Division 132Table 8.3:
Amoytop Biotech – Panel of Recombinant Protein Therapeutics in
Clinical Studies 132Table 8.4: Amoytop Biotech Portfolio of
Patented Y-Shaped Branched Pegylated Recombinant Protein
Therapeutics within Clinical Investigation in China 133Table 8.5: Current Recombinant
protein therapeutics by Amoytop Biotech 133Table 8.6: Active
Pharmaceutical Product Portfolio of Amoytop Biotech 133Table 8.7:
Milestones Achieved by FusoGen Pharmaceuticals 136Table 8.8:
Research and Development Sub-groups of FusoGen Pharmaceuticals
136Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio
137Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test
Profile 137Table 8.11: Shanghai Huaguan Biochip Infectious Disease
Test Portfolio 137Table 8.12: Shanghai Huaguan Biochip Diagnostic
Test Portfolio 137Table 8.13: Shanghai Huaguan Biochip Laboratory
Service Portfolio 130Table 8.14: Intracellular Functions of the
Gene Therapy Agent, Gendicine by SiBiono GeneTech 139Table 8.15:
Gendicine - Potential Oncology Indications for Future Approval
140Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech
141Table 8.17: Important Milestones in the History of Sinovac
Biotech 141Table 8.18: Pipeline Portfolio of Sinovac Biotech
141Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012
144Table 9.1: Key Drivers of the Pharmaceutical Market in
China 149Table 9.2: Key Restraints
of the Pharmaceutical Market in China 150Table 9.3: Key Challenges of the
Pharmaceutical Market in China
151Table 9.4: Patent Expirations of Selected Top Brand Name
Therapeutics by 2020 151Table 9.5: Leading Pharmaceutical Areas
with Significant Opportunities in China 153?
List of Figures
Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in
China, All Ages 14
Figure 3.1: China GDP Figures 2006-2015 19
Figure 3.2: Annual Health Expenditure in China 2006-2015 19
Figure 3.3: Global, Emerging Market & Developing Countries
Economic Growth Change 2010-2013 20
Figure 3.4: Global, Emerging Market & Developing Countries
& China Economic Growth Change 2010-2013 21
Figure 3.5: Global, Emerging Market & Developing Countries
& Russia Economic Growth Change 2010-2013 22
Figure 3.6: Global, Emerging Market and Developing Countries and
India Economic Growth Change 2010-2013 22
Figure 3.7: Global, Emerging Market and Developing Countries and
Brazil Economic Growth Change 2010-2013 23
Figure 3.8: Global, US and Germany Economic Growth 2010-2013
24
Figure 3.9: US and UK Gross Domestic Product per capita Forecast
2010-2017 24
Figure 3.10: Global, France and
Italy Economic Growth 2010-2013 25
Figure 3.11: France, Germay and
Italy Gross Domestic Product per capita Forecast 2010-2017 25
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013
26
Figure 3.13: Global, Japan and
Canada Economic Growth 2010-2013 26
Figure 3.14: China, Brazil and
India Gross Domestic Product per capita Forecast 2010-2017 27
Figure 4.1: The Chinese Healthcare Industry by Sector, 2011
30
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP
Percentage Contribution 2011-2020 46
Figure 5.2: State Drug and Food Administration, China,
Application and Approval Procedure for Imported Drugs 53
Figure 5.3: State Drug and Food Administration, China,
Application and Approval Procedure for Clinical Trials 54
Figure 5.4: Revenue Share (Percentage) of Major Players in
Chinese Pharmaceutical Distribution Market 56
Figure 5.5: Revenue Share (Billion $) of Major Players in
Chinese Pharmaceutical Distribution Market 56
Figure 6.1: Three Tier 'Pharmerging' Markets with Potential for
Significant Growth 58
Figure 6.2: Number of Investigational New Drug Applications in
China 2003-2010 60
Figure 6.3: Number of New Drug Applications in China 2003-2010 61
Figure 6.4: Current Number of Novel Therapeutics in Phase I,
Phase II and Phase III Clinical Trials in China 61
Figure 6.5: Percentage of Clinical Trial Drug by Disease State
62
Figure 6.6: China's Regional Pharmaceutical Processing Trade
Export Market Share Percentage 64
Figure 6.7: Contract Amount of China's Regional Pharmaceutical
Processing Trade Export 64
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of
China 65
Figure 7.1: Abbott Laboratories Geographic Distribution of
Revenue –USA, Established and Emerging Markets 69
Figure 7.2: Abbott Laboratories Established and Emerging Revenue
Share (%) 2012-2015 70
Figure 7.3: Abbott – Business Specialization Strategy 2012:
Diversified Medical Products and Research-Based Pharmaceuticals
70
Figure 7.4: Abbott Diversified Medical Product Portfolio 71
Figure 7.5: AstraZeneca Sales Revenue (US$ Millions) in
China, 2010-2013 79
Figure 7.6: AstraZeneca Global Revenue (Billions) by Geographic
Area: USA, Western Europe, Emerging Markets 2012 79
Figure 7.7: AstraZeneca Cardiovascular Product (Atacand,
Crestor, Seloken/Toprol-XL) Global Sales 2010-2012 81
Figure 7.8: AstraZeneca Gastrointestinal Product (Nexium) Global
Sales 2010-2012 81
Figure 7.9: AstraZeneca Infection Product (Synagis) Global Sales
2010-2012 82
Figure 7.10: AstraZeneca Neuroscience Product (Seroquel-IR, -XR)
Global Sales 2010-2012 82
Figure 7.11: AstraZeneca Oncology Product (Zoladex) Global Sales
2010-2012 83
Figure 7.12: AstraZeneca Respiratory/Inflammation Product
(Pulmicort, Symbicort) Global Sales 2010-2012 83
Figure 7.13: Boehringer Ingelheim Oncology Compounds in
Development 91
Figure 7.14: GlaxoSmithKline Total Sales, Pharmaceutical,
Vaccine and Consumer Healthcare Sales 2012-2013 (£ Billions) 96
Figure 7.15: GlaxoSmithKline Global Pharmaceutical Sales by
Therapeutic Area, 2012-2013 97
Figure 7.16: GlaxoSmithKline Global Vaccine Sales by Therapeutic
Area, 2012-2013 98
Figure 7.17: GlaxoSmithKline Global Sales by Geographic Region –
USA, Europe, Emerging Markets, Japan, 2012-2013 99
Figure 7.18: Johnson & Johnson Pharmaceutical Segment Sales
(US$ Billion) by Therapeutic Area, 2012-2013 103
Figure 7.19: Novartis International Sales (%) by Geographic
Region, 2012-2013 109
Figure 7.20: Novartis International Sales (US$ Millions) by
Geographic Region, 2012-2013 110
Figure 7.21: Novo Nordisk Total China Sales 2009-2013 113
Figure 7.22: Novo Nordsk Total Diabetes Care Market Sales
Performance (DKK Millions) China 2010-2013 113
Figure 7.23: Novo Nordisk Diabetes Care (NovoRapid/NovoLog,
NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin,
Victoza) Sales Performance (DKK Millions) China 2010-2013 114
Figure 7.24: Business Sectors – Pfizer China 116
Figure 7.25: Roche Total Global Sales (CHF Millions) 2012-2013
125
Figure 7.26: Roche Global Sales (CHF Millions) by Therapeutic
Area, 2012-2013 125
Figure 7.27: Roche Pharmaceutical Division Emerging Market Total
Sales 2012-2013 126
Figure 7.28: Roche Pharmaceutical Division Sales from
Brazil, China, India, Mexico, Russia, South
Korea, Turkey, 2012-2013
127
Figure 7.29: Sanofi Geographic Market Share (%) – Emerging
Markets, USA and Western Europe 2012 129
Figure 7.30: Sanofi Geographic Market Share (%) –China,
Russia and USA 2012 130
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and
Clinical Trial Progression 135
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene
Expression (SAGE) Service 138
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012
143
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine,
2009-2012 144
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012 145
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012 145
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012 146
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 146
To order this report: Pharmaceutical Industry in China -
Cutting-Edge Analysis of Multinational and Chinese Pharma
Companies, Industry Trends, Environment, Regulation, Market
Drivers, Restraints, Opportunities & Challenges
http://www.reportlinker.com/p01859471/Pharmaceutical-Industry-in-China---Cutting-Edge-Analysis-of-Multinational-and-Chinese-Pharma-Companies-Industry-Trends-Environment-Regulation-Market-Drivers-Restraints-Opportunities--Challenges.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker